MIBAMPATOR

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H30N2O4S2
Molecular Weight	438.604
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C2=CC=C(CCNS(C)(=O)=O)C=C2

InChI

InChIKey=ULRDYYKSPCRXAJ-KRWDZBQOSA-N

InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H30N2O4S2
Molecular Weight	438.604
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23257314
Curator's Comment: description was created based on several sources, including

Mibampator, also known as LY451395, is a potent and highly selective an AMPA receptor potentiator, which plays a role in the regulation of the glutamatergic system. The AMPA system also has important functions in the regulation of synapses, synaptic regeneration, and neuroprotection and is therefore a good therapeutic target for treatments aiming to improve cognition and function or alter disease progression. Mibampator was in the phase II clinical trial for the treatment of agitation and aggression in Alzheimer's disease (AD).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate receptor ionotropic AMPA 42 Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16554450	Positive Allosteric Modulator 186

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 278 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23257314	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
219 ng/mL EXPERIMENT https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		MIBAMPATOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.082 ng/mL EXPERIMENT https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered:		MIBAMPATOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.8 h EXPERIMENT https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		MIBAMPATOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.39 h EXPERIMENT https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered:		MIBAMPATOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mg 2 times / day multiple, oral Studied dose Dose: 3 mg, 2 times / day Route: oral Route: multiple Dose: 3 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23257314	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23257314	Sources: https://pubmed.ncbi.nlm.nih.gov/23257314

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P0079Z4	https://www.1pchem.com/search?query=1P0079Z4
AK Scientific	2941AH	https://aksci.com/item_detail.php?cat=2941AH
ApexBio Technology	B4658	https://www.apexbt.com/catalogsearch/result/?q=B4658
AstaTech	43003	http://astatechinc.com/CPSResult.php?CRNO=43003
BLD Pharm	BD448313	http://www.bldpharm.com/search/Search.html?keyword=BD448313
Chem Scene	CS-3166	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3166
eMolecules	275134552	https://orderbb.emolecules.com/search/#?query=275134552
eMolecules	301201104	https://orderbb.emolecules.com/search/#?query=301201104
eMolecules	50283017	https://orderbb.emolecules.com/search/#?query=50283017
mcule	MCULE-3421046522	https://mcule.com/MCULE-3421046522/
mcule	MCULE-3661023867	https://mcule.com/MCULE-3661023867/
MedChem Express	HY-10934	https://www.medchemexpress.com/search.html?q=HY-10934&ft=&fa=&fp=
MolPort	MolPort-039-139-412	https://www.molport.com/shop/molecule-link/MolPort-039-139-412
MuseChem	I003378	https://www.musechem.com/product/I003378.html
ShangHai Biochempartner	BCP28335	http://www.biochempartner.com/search_BCP28335

PubMed

Title	Date	PubMed
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.	2013 May	23257314
Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.	2015	26389682

Patents

Sample Use Guides

In Vivo Use Guide

3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:09:01 GMT 2025` Edited by `admin` on `Mon Mar 31 19:09:01 GMT 2025`
Record UNII	A9V5BW73UU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY 451395

Preferred Name

English

MIBAMPATOR

Official Name

English

mibampator [INN]

Common Name

English

LY451395

Code

English

N-((2R)-2-(4'-(2-((METHYLSULFONYL)AMINO)ETHYL)BIPHENYL-4-YL)PROPYL)PROPANE-2-SULFONAMIDE

Systematic Name

English

LY-451395

Code

English

MIBAMPATOR [USAN]

Common Name

English

2-PROPANESULFONAMIDE, N-((2R)-2-(4'-(2-((METHYLSULFONYL)AMINO)ETHYL)(1,1'-BIPHENYL)-4-YL)PROPYL)-

Systematic Name

English

((2R)-2-(4-(4-(2-((METHYLSULFONYL)AMINO)ETHYL)PHENYL)PHENYL)PROPYL)((1-METHYLETHYL)SULFONYL)AMINE

Systematic Name

English

Mibampator [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

300000034286